S&P 500 Healthcare Sector SEC Filings — May 04, 2026

04-05-2026

Akston Biosciences Corp filed an S-1/A for an IPO offering 2,222,222 shares of common stock at a $9.00 midpoint price, expecting net proceeds of approximately $16.1 million (or $18.9 million if underwriters exercise the full 333,333-share over-allotment), to fund USDA facility build-out, AKS-701d pivotal study, and other product pilots like AKS-619d and AKS-548d. Financial results for year-ended December 31, 2025 showed net revenue plunging 99% YoY to $169 thousand from $16.5 million, gross loss of $1.7 million versus $3.0 million profit, and net loss of $28.6 million versus $3.8 million profit, driven by 85% higher R&D expenses despite 18% lower SG&A. Post-IPO, shares outstanding would be 12,285,919 (or 12,619,252 fully diluted), with pro forma as adjusted cash rising to $25.0 million.

• ·Pro forma net loss per share 2025: $(3.24); 2024: $(0.02)
• ·Working capital actual as of Dec 31, 2025: $(4.6M); pro forma: $2.7M; pro forma as adjusted: $20.4M
• ·Total liabilities actual: $50.5M; pro forma: $15.0M; pro forma as adjusted: $14.1M
• ·3.0-for-1 forward stock split effected April 10, 2026
• ·Proposed NYSE American trading symbol: AXTN
• ·$1.00 change in IPO price impacts pro forma as adjusted cash etc. by $2.1M
• ·29,244 warrants cancel if IPO price below $12.70; 29,109 if below $12.01

04-05-2026

Twist Bioscience reported record Q2 FY26 revenue of $110.7 million, up 19% YoY from $92.8 million, driven by 28% growth in DNA Synthesis and Protein Solutions (DSPS) to $53.3 million and 12% growth in NGS Applications to $57.4 million, marking the 13th consecutive quarter of sequential growth. Gross margin improved to 51.6% from 49.6%, but net loss widened to $44.0 million or $0.71 per share from $39.3 million or $0.66 per share, due to SG&A expenses rising to $76.1 million from $63.7 million and a $7.2 million litigation settlement. The company raised FY26 revenue guidance to $442-$447 million (17-19% growth) and reiterated Q4 adjusted EBITDA breakeven, with Q3 revenue expected at $114-$115 million.

• ·R&D expenses decreased to $19.7 million in Q2 FY26 from $23.9 million in Q2 FY25.
• ·Cash, cash equivalents and short-term investments totaled approximately $172 million as of March 31, 2026, down from $232.4 million as of September 30, 2025.
• ·Total assets increased to $676.2 million as of March 31, 2026 from $641.9 million as of September 30, 2025.

04-05-2026

New Mountain Finance Corp reported stable adjusted net investment income of $32.2 million or $0.32 per share for Q1 2026, flat YoY, amid portfolio enhancements and a ~$470 million Secondary Sale completed on March 10, 2026. However, NAV per share declined to $10.92 from $11.52 at December 31, 2025, reflecting the sale, market movements in software loans, and net realized/unrealized losses leading to a $(0.51) per share loss from operations versus $0.22 profit in Q1 2025. The company repurchased ~$66 million of shares YTD at $8.01 average, announced $50 million additional repurchase authorization (remaining capacity ~$80 million), and reduced debt cost on Holdings Credit Facility.

• ·Portfolio composition: 64.7% First Lien, 16.6% Senior Loan Funds (SLP III & IV) & NMNLC, 19.7% other.
• ·91.4% of portfolio fair value rated Green on internal Risk Rating as of March 31, 2026.
• ·Weighted average YTM at Cost of 11.1% as of March 31, 2026.
• ·Reduced cost of debt from SOFR + 1.95% to SOFR + 1.85% on Holdings Credit Facility.
• ·$692.1 million available capacity on credit facilities as of March 31, 2026.
• ·Q2 2026 distribution of $0.25 per share payable June 30, 2026 to holders of record June 16, 2026.

04-05-2026

Artificial Intelligence Technology Solutions Inc. (AITX) filed an 8-K on May 4, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX to Present at the LD Micro Invitational XVI,' attached as Exhibit 99.1. The information is furnished and not deemed filed or material under securities regulations. No financial or operational metrics were disclosed.

04-05-2026

Loews Corporation reported Q1 2026 net income attributable to Loews of $337 million ($1.63 per share), down 9% YoY from $370 million ($1.74 per share), driven by a 23% decline in CNA Financial's net income to $194 million due to lower underwriting results, higher loss ratios, and unfavorable reserve development, while Corporate losses widened to $42 million. However, Boardwalk Pipelines' net income rose 5% to $159 million on higher rates and utilization, and Loews Hotels' net income swung to $26 million from near zero, boosted by joint venture equity income. Book value per share increased slightly QoQ to $90.90 from $90.71.

• ·CNA Property & Casualty combined ratio increased to 102.2% from 98.4% YoY; underlying combined ratio to 94.5% from 92.1%.
• ·Parent company had $4.5 billion cash and investments and $1.8 billion debt as of Mar 31 2026.
• ·Total revenues increased to $4,555 million from $4,494 million YoY.
• ·Book value per share excluding AOCI increased to $97.20 from $95.89 QoQ.

04-05-2026

Aura Biosciences appointed Natalie Holles as Chief Executive Officer, President, and Board member effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D., who stepped down from her roles. The Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) in early choroidal melanoma has enrolled 86 patients as of May 4, 2026, with over 25 additional patients scheduled or identified for screening through May 2026, on track for enrollment completion by mid-2026 and topline data in the second half of 2027. No declines or flat performance metrics were reported.

• ·CoMpass trial is under Special Protocol Assessment agreement with FDA and has Orphan Drug Designation from FDA and EMA, plus Fast Track designation from FDA.
• ·Natalie Holles has over 25 years of experience, including prior CEO roles at Third Harmonic Bio and Audentes Therapeutics.

04-05-2026

CNA Financial reported Q1 2026 net income of $211 million ($0.78 per share), down from $274 million ($1.00 per share) in Q1 2025, with core income of $225 million ($0.83 per share) versus $281 million ($1.03 per share). Property & Casualty core income declined to $248 million from $311 million amid a combined ratio of 102.2% (up from 98.4%) and underlying combined ratio of 94.5% (up from 92.1%), though net written premiums grew 1% to $2,622 million and net investment income rose to $610 million. Life & Group swung to a $9 million core loss from $6 million income, while Corporate & Other loss improved to $14 million from $36 million; the board declared a $0.48 quarterly dividend.

• ·Book value per share excluding AOCI of $45.12, up 1% from year-end 2025 adjusted for $2.48 dividends per share.
• ·New business grew 3% to $581 million with retention at 83%.
• ·Excluding currency, International NWP grew 7%.

04-05-2026

Henderson Brothers Financial Partners, LLC reported $394,858,192 in total 13F securities holdings as of March 31, 2026, across 105 positions, all held with sole voting and investment discretion. The portfolio emphasizes fixed income and equity ETFs, with the largest positions in Fidelity Merrimack STR TR Total BD ETF ($73,302,710), iShares TR 0-3 MNTH TREASRY ($31,399,482), American Century ETF TR Intl Eqt ETF ($27,786,736), and iShares TR US Treas BD ETF ($23,061,042). Individual stocks such as Apple Inc ($1,531,916), Amazon.com Inc ($1,374,372), and NVIDIA Corporation ($2,126,987) represent smaller but notable allocations.

• ·All 105 positions held with sole voting and sole investment discretion power (no shared or other discretion reported).
• ·Filing submitted on May 04, 2026 for period ending March 31, 2026.
• ·Portfolio includes significant exposure to short-term treasuries, international equity ETFs, and U.S. large-cap stocks.

04-05-2026

Bleakley Financial Group, LLC filed its 13F-HR report disclosing $6391593434 in total holdings across 760 positions as of March 31, 2026. Top holdings include iShares Core S&P 500 ETF at $340714736 (521601 shares), Sprott Physical Gold Trust AN at $200087825 (4192955 shares), and Apple Inc at $182153453 (717733 shares). No period-over-period changes or performance metrics are detailed in the filing.

• ·Filed on May 04, 2026 for period ending March 31, 2026
• ·Business address: 300 Kimball Drive, Suite 310, Parsippany, NJ 07054
• ·Contact: 973-244-4213

04-05-2026

Garrison Bradford & Associates Inc filed its 13F-HR on May 4, 2026, reporting holdings as of March 31, 2026, consisting of 38 positions with a total market value of $88,358,799. Top holdings by value include Costco Wholesale ($10,064,939 for 10,101 shares), Quanta Services ($8,685,222 for 15,819 shares), and Blackstone Inc ($7,051,532 for 61,323 shares). Other significant positions are held in UnitedHealth Group, Microsoft, Cheniere Energy, Old Dominion Freight, and Amazon.

• ·All 38 positions held as sole discretionary accounts with 0 shared voting authority.
• ·Filer address: 445 Park Ave., Floor 9, Suite 909, New York, NY 10022.
• ·Additional notable holdings: NVIDIA Corporation (11,597 shares, $2,022,517), Thermo Fisher Scientific (7,450 shares, $3,661,898), TJX Companies (22,615 shares, $3,611,616).

04-05-2026

Nadler Financial Group, Inc. filed its quarterly 13F-HR on May 04, 2026, disclosing 135 equity holdings totaling $1,037,495,791 as of March 31, 2026. The portfolio emphasizes diversified ETFs and large-cap stocks, with top positions in Vanguard Value ETF ($100,314,454), Vanguard Total Stock Market ETF ($73,586,850), and Vanguard S&P 500 ETF ($59,590,816). All holdings are managed with sole investment discretion by Michael A. Nadler, President, CIO, and CCO; no changes or shared voting authority reported.

• ·Report filed under SEC file number 028-14666
• ·All positions reported as SH SOLE with no put/call, shared discretion, or other voting authority
• ·Portfolio includes significant ETF exposure (e.g., Vanguard, Schwab, iShares, State Street products) and individual stocks across technology, consumer, healthcare, and energy sectors

04-05-2026

Financial Institutions Inc (FIISP) reported Q1 2026 net income of $20,985 thousand, up 24.4% YoY from $16,878 thousand, with net interest income rising 10.9% to $51,993 thousand and interest expense declining 13.5% to $29,570 thousand. However, noninterest expense increased 5.7% to $35,595 thousand, comprehensive income fell to $14,688 thousand from $27,487 thousand due to a $6,297 thousand OCI loss, and net loans decreased 0.6% QoQ to $4,582,926 thousand while cash equivalents dropped 21.4% QoQ to $85,451 thousand. Total assets grew modestly 0.3% QoQ to $6,294,783 thousand, supported by 2.5% deposit growth to $5,337,881 thousand.

• ·Basic EPS $1.05 vs $0.82 YoY
• ·Diluted EPS $1.04 vs $0.81 YoY
• ·Provision for credit losses $2,239 thousand vs $2,928 thousand YoY (down 23.5%)
• ·Shareholders’ equity $631,670 thousand at Mar 31 2026, up from $628,854 thousand at Dec 31 2025
• ·Net cash used in investing activities $55,787 thousand vs $147,288 thousand YoY

04-05-2026

Franklin Financial Services Corporation (FRAF) filed an 8-K/A on May 4, 2026, amending its May 1, 2026 original 8-K to include Exhibit 99.2, the Shareholder Presentation from the annual shareholder meeting held on April 28, 2026. The filing furnishes under Item 7.01 an Investor Presentation (Exhibit 99.1) for use in investor and analyst meetings, available on the company's website at www.franklinfin.com. No financial results or performance metrics are disclosed in the filing.

• ·Annual meeting of shareholders held on April 28, 2026.
• ·Securities registered: Common stock (FRAF) on Nasdaq Capital Market.
• ·Principal executive office: 1500 Nitterhouse Drive, Chambersburg, PA 17201.

04-05-2026

Gilead Sciences, Inc. held its 2026 Annual Meeting on April 30, 2026, where stockholders elected all nine director nominees with strong support (ranging from 94.8% to 98.5% of votes cast), ratified Ernst & Young LLP as independent auditors (92.5% approval), approved advisory executive compensation (91.5%), and approved the amended and restated 2022 Equity Incentive Plan (93.7%). However, three stockholder proposals failed decisively: independent Board Chair policy (27.0% support), report on extended patent exclusivities' impact on patient access (13.2% support), and report on ESG/DEI risks in compensation (0.7% support). A quorum was present with 1,130,179,690 shares represented out of 1,241,222,013 entitled to vote.

• ·Director election votes: Jacqueline K. Barton - 1,013,176,696 For, 21,056,724 Against; Daniel P. O’Day (lowest For) - 980,597,212 For, 50,179,985 Against.
• ·Auditor ratification: 1,046,350,569 For, 82,831,295 Against.
• ·Executive compensation: 954,325,805 For, 77,503,947 Against.
• ·Equity Plan: 970,290,586 For, 62,501,433 Against.
• ·Independent Chair proposal: 280,044,780 For, 752,716,225 Against.
• ·Patent report proposal: 134,042,210 For, 886,986,584 Against.
• ·ESG/DEI report proposal: 7,262,421 For, 1,022,330,186 Against.

04-05-2026

Vertex reported Q1 2026 total revenue of $2.99 billion, up 8% YoY from Q1 2025, driven by strong CF performance, U.S. ALYFTREK initiations, and contributions from CASGEVY ($43 million) and JOURNAVX ($29 million), which accounted for over 25% of growth. However, combined GAAP R&D, Acquired IPR&D, and SG&A expenses rose to $1.5 billion from $1.4 billion YoY due to investments in JOURNAVX launch and renal franchise build-out, while the VX-522 CF program was terminated due to tolerability issues. The company reiterated FY 2026 revenue guidance of $12.95 to $13.1 billion, including $500 million or more from non-CF products.

• ·VX-522 CFTR modulator program terminated after Phase 1/2 due to persistent tolerability issues, precluding further development.
• ·Povetacicept rolling BLA submitted to FDA for accelerated approval in IgAN using Priority Review Voucher; Phase 3 in pMN initiated.
• ·CASGEVY U.S. regulatory submission completed for ages 5 to <12 years in SCD/TDT; awarded FDA National Priority Voucher.
• ·JOURNAVX added to CMS NOPAIN Act separate payment list (retroactive Jan 23, 2026); agreement with major PBM for Medicare Part D coverage (10M lives, effective May 1).
• ·FY 2026 guidance unchanged: non-CF revenue $500M+; combined GAAP expenses $6.3-6.45B; non-GAAP $5.65-5.75B.

04-05-2026

At the annual stockholder meeting on April 30, 2026, Intuitive Surgical's shareholders elected all ten Board nominees with overwhelming support (e.g., David J. Rosa received 282,229,466 For votes), approved the advisory say-on-pay for named executive officers (265,030,878 For), ratified PricewaterhouseCoopers LLP as independent auditors (308,789,950 For), and approved the Amended 2010 Incentive Award Plan, increasing shares reserved from 120,350,000 to 125,350,000 and extending the term to January 29, 2036. The Board also increased the common stock repurchase program authorization to an aggregate of $5.0 billion. All proposals passed decisively with minimal opposition.

• ·Proposal 2 Against votes: 17,018,702
• ·Proposal 4 Against votes: 22,129,032 (highest opposition among proposals)

04-05-2026

Evernest Financial Advisors, LLC, an Indiana-based investment advisor, filed its 13F-HR report on May 04, 2026, for the quarter ended March 31, 2026, disclosing total 13F holdings valued at $481407058 across 180 positions, all reported as sole discretionary. Top holdings include Apple Inc. COM at $36160035, Berkshire Hathaway Inc DEL CL B NEW at $30477805, and Microsoft Corp COM at $21408514. The portfolio features a diverse mix of individual stocks, ETFs, and funds with no other voting authority reported.

• ·Filer CIK: 0002009530
• ·SEC File Number: 028-23795
• ·Business Address: 75 EXECUTIVE DRIVE, SUITE B, CARMEL, IN 46032
• ·Phone: 3175561015

04-05-2026

On May 4, 2026, the Board of Directors of Hewlett Packard Enterprise Company (HPE) approved a cash dividend of $0.953125 per share on its 7.625% Series C Mandatory Convertible Preferred Stock, payable on June 1, 2026, to holders of record as of the close of business on May 15, 2026. The declaration and payment are subject to the Board's sole discretion and must come from legally available sources.

• ·If the dividend payment date is not a business day, payment will be made on the next succeeding business day without interest or other payment in lieu thereof.
• ·Information in Item 7.01 is not deemed 'filed' under Section 18 of the Exchange Act or incorporated by reference into any Securities Act filing.

04-05-2026

Norwood Financial Corp held its Annual Meeting of Stockholders on April 28, 2026, where all three proposals were approved. Stockholders elected Kevin M. Lamont, Dr. Kenneth A. Phillips, and Jeffrey S. Gifford as directors for three-year terms; ratified the appointment of S.R. Snodgrass, P.C. as independent registered public accounting firm for the year ending December 31, 2026; and approved a non-binding advisory resolution on named executive officer compensation.

04-05-2026

Axos Financial, Inc. filed an 8-K under Items 7.01 and 9.01 for Regulation FD Disclosure, announcing the use of investor presentation materials (Exhibits 99.1 and 99.2) at investor meetings beginning on or around May 5, 2026. The information is presented as of May 4, 2026, and is not deemed 'filed' for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings.

• ·Filing Date: May 4, 2026
• ·Date of Report (earliest event): May 4, 2026
• ·Investor meetings: beginning on or around May 5, 2026
• ·Trading Symbol: AX on New York Stock Exchange
• ·Commission File Number: 001-37709
• ·IRS Employer Identification Number: 33-0867444
• ·Principal executive offices: 9205 West Russell Road, Ste 400, Las Vegas, NV 89148

04-05-2026

TOEWS CORP /ADV filed its 13F-HR on May 04, 2026, for the period ending March 31, 2026, disclosing total holdings valued at $259,212,630,000 across 6 ETF positions. The largest position is ISHARES TR CORE S&P500 ETF at $245,443,658,000 (375,750 shares), with other significant holdings in PGIM ETF TR AAA CLO ETF ($6,521,867,000) and NORTHERN LIGHTS FD TR TOEWS AGILTY SHS ($2,816,913,000). No period-over-period changes are reported in the filing.

• ·Filing covers period ending March 31, 2026 (Q1 2026)
• ·All positions reported as SOLE ownership

04-05-2026

OneWater Marine Inc. reported total revenues of $442.3M for the three months ended March 31, 2026, down 8.5% YoY from $483.5M, driven by a 12.1% decline in new boat sales to $272.0M, though pre-owned boat revenues increased 5.2% to $94.4M; service, parts & other fell 10.7% to $61.9M. For the six months ended March 31, 2026, revenues declined 4.3% YoY to $822.9M, with net loss widening to $20.6M from $14.0M, impacted by $14.0M in restructuring and impairment charges. Balance sheet showed total assets at $1,376M, down from $1,404M at September 30, 2025, with inventories up slightly to $551.4M but stockholders' equity decreasing to $269.4M.

• ·Operating cash flow used $23.8M for six months ended March 31, 2026, worsening from $9.0M used in prior year.
• ·Notes payable – floor plan increased to $473.1M from $419.7M at September 30, 2025.
• ·Stockholders’ equity declined to $269.4M from $285.0M at September 30, 2025.
• ·Proceeds from disposal of a business: $48.7M in investing activities six months ended March 31, 2026.

04-05-2026

First Western Financial, Inc.'s Board of Directors authorized a share repurchase program of up to $5,000,000 of its common stock on April 22, 2026, with the Federal Reserve Board of Governors providing no objection on April 29, 2026. The Repurchase Plan is effective for one year beginning June 12, 2026, and may be conducted through open market purchases, private negotiations, or Rule 10b5-1 trading plans. The program does not obligate the Company to repurchase any specific amount or number of shares and can be modified or terminated at any time.

• ·Repurchases must comply with applicable federal securities laws.
• ·The prior active Repurchase Plan expires on June 12, 2026.

04-05-2026

Merck & Co., Inc. reported Q1 2026 sales of $16,286 million, up 4.9% YoY from $15,529 million, with alliance revenues rising 41% to $502 million driven by Koselugo (+266%) and Lynparza (+9%), while Lenvima remained flat. However, a $8,540 million research and development asset acquisition charge contributed to a net loss of $4,240 million versus a $5,079 million profit in Q1 2025, alongside sharply higher R&D expenses of $12,592 million (up 248% YoY). Cash from operations improved 57% to $3,918 million, but cash and equivalents fell to $5,327 million from $14,565 million at year-end, reflecting an $8,779 million acquisition of Cidara Therapeutics.

• ·Total current assets declined to $35,015 million from $43,516 million at Dec 31, 2025.
• ·Adempas/Verquvo total sales increased 7.1% YoY to $196 million.
• ·Treasury stock increased to 1,107,410,143 shares from 1,102,476,756 shares at Dec 31, 2025.

04-05-2026

Tidewater Inc. reported first quarter 2026 revenue of $326.2 million, a 2.2% YoY decline from $333.4 million, and net income of $6.1 million, down sharply from $42.7 million in Q1 2025, adversely impacted by a $3.4 million foreign exchange loss due to USD strengthening. However, results exceeded internal expectations with a 48.8% gross margin, average day rate of $22,283 (up nearly $240 QoQ), and strong vessel utilization. The company reiterated 2026 revenue guidance of $1.43-1.48 billion with 49-51% gross margins pro forma for the Wilson Sons Ultratug acquisition and announced a $500 million share repurchase program authorization.

• ·Conference call scheduled for May 5, 2026 at 8:00 a.m. Central Time.
• ·Expected acquisition close of Wilson Sons Ultratug by end of Q2 2026.
• ·22-vessel fleet in Wilson Sons Ultratug acquisition focused on Brazilian market.

04-05-2026

Corebridge Financial, Inc. announced excellent progress toward closing its transformative merger with Equitable Holdings, Inc., with regulatory filings on track, leadership team finalized for announcement shortly, and a new integration management office established for seamless transition. However, the communication includes extensive cautionary forward-looking statements highlighting risks such as failure to obtain approvals, integration difficulties, business disruptions, and potential adverse impacts on stock price, operations, and personnel retention.

• ·Corebridge proxy statement for 2025 Annual Meeting filed April 16, 2025.
• ·Equitable Holdings proxy statement for 2025 Annual Meeting filed April 4, 2025.
• ·Annual Reports on Form 10-K for year ended December 31, 2025.
• ·Registration Statement on Form S-4 to be filed by new parent company.

04-05-2026

Broadview Financial Management, LLC filed a 13F-HR report disclosing its equity holdings as of March 31, 2026, totaling $146,426,934 across 40 positions, all in ETFs with sole voting authority. The portfolio is heavily weighted toward diversified index ETFs including U.S. large-cap, small-cap, growth, value, REITs, international developed, emerging markets, and total bond market exposures from issuers like Schwab, Vanguard, iShares, and State Street. No changes or performance metrics were detailed in the filing.

• ·All holdings reported with sole voting authority (columns show 0 for shared and none in most cases)
• ·Portfolio focused exclusively on passive ETFs tracking major indices, no individual stocks
• ·Filing covers period ended 03-31-2026, submitted 05-04-2026

04-05-2026

Fortress Financial Solutions, LLC filed its 13F-HR report disclosing $95,707,588 in total holdings across 106 positions as of March 31, 2026. Top holdings include Invesco QQQ Trust ($9,651,797), Vanguard Scottsdale Fds Int-Term Corp ($7,735,682), iShares Preferred and Income Securities ETF ($5,087,431), and Apple Inc. ($3,697,989). The portfolio features a mix of individual stocks and ETFs with both sole discretionary and defined shares, but no period-over-period changes are detailed in this snapshot filing.

• ·Report filed on May 04, 2026 for period ending March 31, 2026
• ·Central Index Key: 0002039501
• ·State of Incorporation: AZ
• ·Other notable holdings include NVIDIA Corporation ($1,308,281), JPMorgan Exchange-Traded F Nasdaq Eqt Prem ($2,646,491), and iShares TR Core S&P MCP ETF ($4,380,535)

04-05-2026

New Jersey Resources reported fiscal 2026 Q2 consolidated net financial earnings (NFE) of $221.5 million, up 24% YoY from $178.3 million, driven by Energy Services' strong performance ($72.3 million, +105% YoY) and NJNG growth ($148.5 million, +3% YoY), leading to a second upward revision of FY2026 NFEPS guidance to $3.48-$3.63. Year-to-date NFE reached $339.6 million, +11% YoY. However, Clean Energy Ventures reported a wider Q2 NFE loss of $5.2 million (vs. $4.0 million prior) and YTD NFE fell 90% to $4.4 million due to absence of prior-year asset sale gain.

• ·NJNG BGSS incentives contributed $17.3M to utility gross margin H1 FY2026 vs. $10.6M prior year.
• ·SAVEGREEN® invested $46.5M in H1 FY2026 energy-efficiency upgrades.
• ·FY2026 expected NFE contributions: NJNG 58-62%, CEV 9-13%, S&T 8-11%, ES 19-23%, Home Services 0-1%.
• ·H1 FY2026 capex $353.9M vs. $287.1M prior year.

04-05-2026

ARTELO BIOSCIENCES, INC. (ARTL) filed a Form S-3 shelf registration statement on May 4, 2026, enabling the potential future issuance of an unlimited amount of various securities, including common stock, preferred stock, debt securities, warrants, and units. Net proceeds would be used for working capital, general corporate purposes, or potential acquisitions/licenses, though no specific transactions or amounts are committed. The filing incorporates by reference the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on February 24, 2026.

• ·Debt securities may be issued under an indenture with a trustee (to be specified in prospectus supplement).
• ·No protection for holders in the event of a change of control unless specified otherwise.
• ·Capital stock description incorporated by reference from Exhibit 4.1 of 10-K for FY ended December 31, 2025.

04-05-2026

Edwards Lifesciences Corporation announced the appointment of Theodora (“Doretta”) Mistras as corporate vice president and chief financial officer (CFO), effective at the end of May 2026, succeeding Scott Ullem who has served as CFO since 2014 and announced his planned transition in October. Mistras joins from Viatris, where she has been CFO since March 2024, with prior senior roles in healthcare investment banking at Citigroup Global Markets and Goldman Sachs. CEO Bernard Zovighian highlighted her experience as instrumental for executing the company's strategy and delivering long-term value.

• ·Mistras holds a bachelor’s degree in international studies from the University of Pennsylvania and a bachelor’s degree in economics from the Wharton School.
• ·Ullem will continue as a strategic advisor in the months ahead.

04-05-2026

Zions Bancorporation, N.A. sold 460,153 Class B-1 shares of Visa Inc., originally received in 2007, for aggregate proceeds of $215 million on May 4, 2026. This transaction resulted in a pre-tax gain of approximately $215 million to be recognized in the second quarter of 2026. No other comparative or negative financial impacts were disclosed.

• ·Shares were received in 2007 in connection with a restructuring and public offering by Visa U.S.A.

04-05-2026

WSFS Financial Corp reported net income attributable to WSFS of $86,827 thousand for Q1 2026, up 32% YoY from $65,896 thousand, driven by 6% higher net interest income of $185,136 thousand and a $19,348 thousand swing to a release of credit loss provision versus a prior-year provision; diluted EPS rose to $1.64 from $1.12. However, interest and fees on loans and leases declined 5% to $205,243 thousand, noninterest expenses increased 7% to $162,765 thousand, and total comprehensive income fell sharply to $78,287 thousand from $141,299 thousand due to an $8,540 thousand other comprehensive loss.

• ·Diluted EPS $1.64 in Q1 2026 vs $1.12 in Q1 2025.
• ·Cash dividend of $0.17 per share in Q1 2026 vs $0.15 in Q1 2025.
• ·Weighted average diluted shares outstanding 53,031,912 in Q1 2026 vs 58,713,452 in Q1 2025.
• ·Net cash provided by operating activities $86,373 thousand in Q1 2026 vs $8,746 thousand in Q1 2025.

04-05-2026

Central Pacific Financial Corp. held its Annual Meeting of Shareholders on April 30, 2026, where all ten director nominees were elected with strong majority support ranging from 87.9% to 89.4% of votes cast. Shareholders also approved the non-binding Say-on-Pay resolution with approximately 87.7% support and ratified the appointment of Crowe LLP as independent auditor for the fiscal year ending December 31, 2026, with nearly 99.7% approval. No significant opposition or abstentions were noted across proposals.

• ·Broker non-votes: 1,369,298 for director elections and Say-on-Pay
• ·Say-on-Pay abstentions: 15,119
• ·Auditor ratification against votes: 82,192; abstentions: 6,514

04-05-2026

Empirical Financial Services, LLC d.b.a. Empirical Wealth Management filed its 13F-HR on May 4, 2026, disclosing institutional holdings totaling $5,784,702,776 as of March 31, 2026, across 1706 positions. Top holdings include Apple Inc. COM (value $142,593,953 SOLE), Amazon.com Inc. COM (value $58,243,066 SOLE), Alphabet Inc. CAP STK CL C (value $40,585,654 SOLE), and Altria Group Inc. COM (value $23,431,634 SOLE). The portfolio features significant allocations to technology giants alongside diversified exposure to ETFs, financials, and healthcare.

• ·Filing covers period ending 03-31-2026
• ·Business address: 1420 5TH AVE SUITE 3150, Seattle WA 98101
• ·Phone: 206-923-3474

04-05-2026

Lutz Financial Services LLC filed its 13F-HR report on May 4, 2026, disclosing $1,487,908,153 in total equity holdings across 100 positions as of March 31, 2026. The portfolio features a diversified mix dominated by ETFs from iShares, Vanguard, Dimensional, Schwab, and SPDR, with top positions including Vanguard S&P 500 ETF ($150,605,249), iShares Core S&P Mid-Cap ETF ($107,944,964), and Vanguard Total Bond Market ETF ($105,389,155), alongside individual stocks like Nvidia ($1,793,704), Apple ($1,535,937), and Microsoft ($1,147,527). No period-over-period changes are detailed in the filing.

• ·Business address: 13616 California St, Suite 200, Omaha, NE 68154
• ·Phone: 402-827-2300
• ·SEC file number: 028-18716

04-05-2026

Esquire Financial Holdings, Inc. filed an S-4/A registration statement on May 4, 2026, as part of a proposed merger with Signature, convening a special stockholder meeting on June 23, 2026, to vote on the issuance of Esquire common stock to Signature shareholders and an adjournment proposal. As of the record date of April 29, 2026, 8,639,431 shares of Esquire common stock were outstanding, with directors and executive officers entitled to vote 1,148,523 shares, representing 13.3%. The Esquire board unanimously recommends voting 'FOR' both proposals.

• ·Quorum requires holders of a majority of outstanding shares present in person or by proxy.
• ·Esquire share issuance proposal requires majority of votes cast; abstentions and failures to vote have no effect.
• ·Meeting location: 100 Jericho Quadrangle, Suite 100, Jericho, New York 11753; teleconference: 800-715-9871, code 9572322.

04-05-2026

Occidental Petroleum (NYSE: OXY) announced CEO succession as part of management planning: Vicki Hollub will retire as President and CEO effective June 1, 2026, with Senior Vice President and Chief Operating Officer Richard Jackson named as her successor. Hollub, CEO since 2016, will continue on the Board for continuity, while Jackson will join the Board on the same date. The leadership praised the company's strong portfolio and technical expertise post-transformation.

• ·Announcement dated May 1, 2026; filing dated May 04, 2026.
• ·Jackson joined Occidental in 2003; prior roles include President of U.S. Onshore Oil and Gas and President of Low Carbon Integrated Technologies.
• ·Hollub has over 40 years at Occidental; Board member since 2015.
• ·Media contact: Eric Moses (713-497-2017); Investor contact: Babatunde A. Cole (713-552-8811).

04-05-2026

LCI Industries filed an 8-K on May 4, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits), referencing a press release dated May 4, 2026, attached as Exhibit 99.1. The filing contains no specific financial data, performance metrics, or event details beyond the press release reference.

• ·Securities registered: Common Stock, $.01 par value (LCII on New York Stock Exchange)
• ·Principal executive offices: 3501 County Road 6 East, Elkhart, Indiana 46514
• ·Telephone: (574) 535-1125

04-05-2026

Rallybio Corporation (RLYB) executed a waiver on May 1, 2026, to its March 1, 2026 merger agreement with Candid Therapeutics, Inc., allowing Candid to pursue acquisition proposals from UCB S.A. without notice periods or breach claims, effectively paving the way for termination of the Rallybio deal. Upon termination and entry into a UCB agreement, Candid must pay Rallybio a $50,000,000 Parent Termination Fee plus $375,000 reimbursement by May 4, 2026. No other financial impacts or ongoing obligations are noted post-payment.

• ·Waiver permits termination via Section 9.1(h) without concurrent fee payment requirement, but fee still obligatory
• ·Waiver also releases restrictions under Company Stockholder Support Agreement Section 1.7 for UCB proposals
• ·Post-payment, all parties released from further claims related to the agreement or contemplated transactions
• ·Original merger agreement dated March 1, 2026

04-05-2026

Bridgewater Bancshares, Inc. furnished an Investor Presentation dated May 4, 2026, under Item 7.01 Regulation FD Disclosure for use by executives in investor and analyst meetings. The presentation is attached as Exhibit 99.1 and not deemed 'filed' under Section 18 of the Exchange Act. No specific financial metrics or performance data are disclosed in the filing itself.

• ·Securities registered: Common Stock (BWBB) and Depositary Shares (BWBBP) on The NASDAQ Stock Market LLC
• ·Filing signed by Jerry Baack on May 4, 2026

04-05-2026

News Corporation filed an 8-K disclosing details of its ongoing stock repurchase program, authorizing up to $1 billion in aggregate purchases of Class A (NWSA) and Class B (NWS) common stock. The company attached Exhibits 99.1 and 99.2 containing information provided to the Australian Securities Exchange (ASX) on respective dates, fulfilling daily disclosure requirements under ASX rules. No specific repurchase transactions or amounts were detailed in the filing.

• ·Filing reports earliest event date of May 1, 2026.
• ·Securities registered: Class A Common Stock (NWSA) and Class B Common Stock (NWS) on Nasdaq Global Select Market.